Apr 15, 2026 06:59AM Actuate Therapeutics (ACTU) PT Lowered to $8 at B.Riley

Apr 13, 2026 06:40AM Actuate Therapeutics (ACTU) PT Lowered to $15 at H.C. Wainwright

Mar 24, 2026 07:01AM Actuate Therapeutics advances oral elraglusib formulation and pediatric trials

Mar 24, 2026 07:00AM Actuate Therapeutics: Poised for Potential $200M+ Pediatric Priority Review Vouchers and Transformative Combinations in RAS-Driven Cancers

Jan 15, 2026 06:45AM H.C. Wainwright Reiterates Buy Rating on Actuate Therapeutics (ACTU)

Jan 6, 2026 02:26PM Lucid Capital Markets Reiterates Buy Rating on Actuate Therapeutics (ACTU)

Dec 15, 2025 08:45AM Actuate Therapeutics publishes phase II salivary gland cancer data

Sep 23, 2025 06:37AM H.C. Wainwright Reiterates Buy Rating on Actuate Therapeutics (ACTU)

Sep 22, 2025 08:45AM Actuate Therapeutics updates FDA on pancreatic cancer drug trial data

Aug 26, 2025 01:08AM B.Riley Starts Actuate Therapeutics (ACTU) at Buy

Aug 6, 2025 08:45AM Actuate Therapeutics starts pancreatic cancer trial with Incyte, Pittsburgh

Jul 25, 2025 04:03PM Actuate Therapeutics (ACTU) Files for 1.33M Share Offering by Selling Stockholders

Jul 21, 2025 06:46AM H.C. Wainwright Reiterates Buy Rating on Actuate Therapeutics (ACTU)

Jun 20, 2025 08:45AM Actuate Therapeutics (ACTU) Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial

May 22, 2025 05:29PM Actuate Therapeutics (ACTU) announces publication of abstract ahead of ASCO 2025

May 6, 2025 08:01AM Actuate Therapeutics (ACTU) Announces Statistically Significant Topline Results from Global Phase 2 Trial of Elraglusib in First-Line Treatment of MPC

Apr 22, 2025 09:02AM Craig-Hallum Starts Actuate Therapeutics (ACTU) at Buy

Feb 25, 2025 08:04AM Actuate Therapeutics (ACTU) Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic

Jan 7, 2025 08:03AM Actuate Therapeutics (ACTU) Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer

Dec 17, 2024 08:02AM Actuate Therapeutics (ACTU) Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer

Nov 12, 2024 08:04AM Actuate Therapeutics (ACTU) Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcoma

Sep 11, 2024 08:00AM Actuate Therapeutics (ACTU) Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Soft Tissue Sarcomas

Sep 9, 2024 08:01AM Actuate Therapeutics (ACTU) Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma

Jul 23, 2024 06:07AM Actuate Therapeutics (ACTU) Announces 2M Share IPO at $8-$10/sh

Jul 19, 2024 08:00AM Actuate Therapeutics (ACTU) Files for 2.78M Share Offering by Selling Stockholders

Jun 11, 2024 07:04AM Actuate Therapeutics (ACTU) Announces 5.56M Share IPO at $8-$10/sh